Sami Inkinen

And we have this a little bit of a crazy mission, reverse type two diabetes and obesity in 1 billion people, reverse type two diabetes and obesity in 1 billion people. And yeah, here we are 10 years later and we can go into details. How's it going? But yeah, Yeah, that's how I became an accidental healthcare entrepreneur.

And we have this a little bit of a crazy mission, reverse type two diabetes and obesity in 1 billion people, reverse type two diabetes and obesity in 1 billion people. And yeah, here we are 10 years later and we can go into details. How's it going? But yeah, Yeah, that's how I became an accidental healthcare entrepreneur.

And honestly, it's been the most rewarding journey in my professional career so far.

And honestly, it's been the most rewarding journey in my professional career so far.

And honestly, it's been the most rewarding journey in my professional career so far.

By the way, I'll add here, I think Krisma mentioned the IUH trial, so Indiana University Health and data, which is that when we started Virta, obviously, we use telemedicine and nutrition to achieve these results. And when you use telemedicine and nutrition, you don't need FDA approval. It's not a new molecule that we are developing, a new drug.

By the way, I'll add here, I think Krisma mentioned the IUH trial, so Indiana University Health and data, which is that when we started Virta, obviously, we use telemedicine and nutrition to achieve these results. And when you use telemedicine and nutrition, you don't need FDA approval. It's not a new molecule that we are developing, a new drug.

By the way, I'll add here, I think Krisma mentioned the IUH trial, so Indiana University Health and data, which is that when we started Virta, obviously, we use telemedicine and nutrition to achieve these results. And when you use telemedicine and nutrition, you don't need FDA approval. It's not a new molecule that we are developing, a new drug.

But we made this what at the time, this was 2015, seemed like a crazy risky bet. That is, we started a five-year prospective clinical trial with practically no funding for the company. And most of my investors were sort of from the tech world and they were rolling their eyes and saying, are you crazy? You're gonna spend five years doing a clinical trial.

But we made this what at the time, this was 2015, seemed like a crazy risky bet. That is, we started a five-year prospective clinical trial with practically no funding for the company. And most of my investors were sort of from the tech world and they were rolling their eyes and saying, are you crazy? You're gonna spend five years doing a clinical trial.

But we made this what at the time, this was 2015, seemed like a crazy risky bet. That is, we started a five-year prospective clinical trial with practically no funding for the company. And most of my investors were sort of from the tech world and they were rolling their eyes and saying, are you crazy? You're gonna spend five years doing a clinical trial.

Now with hindsight, it is one of the best things that we've ever done. And obviously we keep publishing data and we have other trials in the works, but the reason it was such a good move at the time is one, Obviously, we've attracted people like Griezmann to join the company who say, hey, I want to know if this actually works. Is this safe? What's the sustainability?

Now with hindsight, it is one of the best things that we've ever done. And obviously we keep publishing data and we have other trials in the works, but the reason it was such a good move at the time is one, Obviously, we've attracted people like Griezmann to join the company who say, hey, I want to know if this actually works. Is this safe? What's the sustainability?

Now with hindsight, it is one of the best things that we've ever done. And obviously we keep publishing data and we have other trials in the works, but the reason it was such a good move at the time is one, Obviously, we've attracted people like Griezmann to join the company who say, hey, I want to know if this actually works. Is this safe? What's the sustainability?

And I don't want to hear white papers and marketing materials and be like, show me the hard data. Is it peer reviewed? And I can go through. So that's kind of the one reason. But then the second reason is, which I didn't appreciate coming from outside of health care. paradigms, even in light of new data, change very slowly. Very, very slowly. Like you, Mark, mentioned, oh, diabetes is reversible.

And I don't want to hear white papers and marketing materials and be like, show me the hard data. Is it peer reviewed? And I can go through. So that's kind of the one reason. But then the second reason is, which I didn't appreciate coming from outside of health care. paradigms, even in light of new data, change very slowly. Very, very slowly. Like you, Mark, mentioned, oh, diabetes is reversible.

And I don't want to hear white papers and marketing materials and be like, show me the hard data. Is it peer reviewed? And I can go through. So that's kind of the one reason. But then the second reason is, which I didn't appreciate coming from outside of health care. paradigms, even in light of new data, change very slowly. Very, very slowly. Like you, Mark, mentioned, oh, diabetes is reversible.

Well, guess what? If we go and poll 1,000 average or random providers, you know, Harvard trains, Stanford train, you name it, I don't know what percentage would still say, yeah, no, no, type two diabetes, it's chronic, progressive, you can't reverse it.

Well, guess what? If we go and poll 1,000 average or random providers, you know, Harvard trains, Stanford train, you name it, I don't know what percentage would still say, yeah, no, no, type two diabetes, it's chronic, progressive, you can't reverse it.

Well, guess what? If we go and poll 1,000 average or random providers, you know, Harvard trains, Stanford train, you name it, I don't know what percentage would still say, yeah, no, no, type two diabetes, it's chronic, progressive, you can't reverse it.